Interindividual variability in acetaminophen sulfation by human fetal liver: Implications for pharmacogenetic investigations of drug-induced birth defects

Birth Defects Research Part A - Clinical and Molecular Teratology

Volumn 82, Issue 3, 2008, Pages 155-165

  Adjei, Araba A ^a,c   Gaedigk, Andrea ^b   Simon, Stephen D ^b   Weinshilboum, Richard M ^a   Leeder, J Steven ^b  

^a MAYO GRADUATE SCHOOL   (United States)

^b CHILDREN S MERCY HOSPITAL   (United States)

^c ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

Acetaminophen; Fetal liver; Sulfotransferase; SULT

Indexed keywords

PARACETAMOL; SULFOTRANSFERASE; SULFOTRANSFERASE 1A1; SULFOTRANSFERASE 1A3; SULFOTRANSFERASE 1A4; SULFOTRANSFERASE 1E1; SULFOTRANSFERASE 2A1; UNCLASSIFIED DRUG;

ARTICLE; BIRTH DEFECT; CATALYSIS; CONTROLLED STUDY; DRUG INDUCED DISEASE; DRUG SULFATION; FETUS LIVER; GASTROSCHISIS; GENETIC VARIABILITY; HUMAN; HUMAN TISSUE; PRIORITY JOURNAL; RISK FACTOR;

ABNORMALITIES, DRUG-INDUCED; ACETAMINOPHEN; HUMANS; LIVER; PHARMACOGENETICS; SULFATES; SULFOTRANSFERASES;

EID: 41449096769     PISSN: 15420752     EISSN: 15420760     Source Type: Journal    
DOI: 10.1002/bdra.20535     Document Type: Article

References (40)

1. Adjei AA, Weinshilboum RM. 2002. Catecholestrogen sulfation: possiblerole in carcinogenesis. Biochem Biophys Res Commun 292:402-408.
2. Andrade SE, Gurwitz JH, Davis RL, et al. 2004. Prescription drug use in pregnancy. Am J Obstet Gynecol 191:398-407.
3. Barker EV, Hume R, Hallas A, et al. 1994. Dehydroepiandrosterone sulfotransferase in the developing human fetus: quantitative biochemical and immunochemical characterization of the hepatic, renal, and adrenal enzymes. Endocrinology 134:982-989.
4. Bessems JG, Vermeulen NP. 2001. Paracetamol (acetaminophen)-induced toxicity: molecular and biochemical mechanisms, analogues and protective approaches. Crit Rev Toxicol 31:55-138.
5. Bock KW, Forster A, Gschaidmeier H, et al. 1993. Paracetamol glucuronidation by recombinant rat and human phenol UDP-glucuronosyl- transferases. Biochem Pharmacol 45:1809-1814.
6. Campbell NR, Van Loon JA, Weinshilboum RM. 1987. Human liver phenol sulfotransferase: assay conditions, biochemical properties and partial purification of isozymes of the thermostable form. Biochem Pharmacol 36:1435-1446.
7. Cappiello M, Guiliani L, Rane A, et al. 1991. Dopamine sulphotransferase is better developed than p-nitrophenol sulphotransferase in the human fetus. Develop Pharmacol Ther 16:83-88.
8. CDC. 2007. Hospital stays, hospital charges, and in-hospital deaths among infants with selected birth defects - United States, 2003. Morbid Mortal Weekly Rep 56:25-29.
9. Coughtrie MWH. 2002. Sulfation through the looking glass - recent advances in sulfotransferase research for the curious. Pharmacogenomics J 2:297-308.
10. Coughtrie MWH, Burchell B, Leakey JA, et al. 1988. The inadequacy of perinatal glucuronidation: Immunoblot analysis of the developmental expression of individual UDP-glucuronosyltransferase isoenzymes in rat and human liver microsomes. Mol Pharmacol 34:729-735.
11. Duanmu Z, Weckle A, Koukouritaki SB, et al. 2006. Developmental expression of aryl, estrogen, and hydroxysteroid sulfotransferases in pre- and postnatal human liver. J Pharmacol Exp Ther 316:1310-1317.
12. Foldes A, Meek JL. 1973. Rat brain phenolsulfotransferase - partial purification and some properties. Biochim Biophys Acta 327:365-374.
13. Gonzalez FJ. 2005. Role of cytochromes P450 in chemical toxicity and oxidative stress: studies with CYP2E1. Mutat Res 560:101-110.
14. Hebbring SJ, Adjei AA, Baer JL, et al. 2007. Human SULT1A1 gene: Copy number differences and functional implications. Hum Mol Genet 16:463-470.
15. Hernandez JS, Powers SP, Weinshilboum RM. 1991. Human liver arylamine N-sulfotransferase activity. Thermostable phenol sulfotransferase catalyzes to N-sulfation of 2-naphthylamine. Drug Metab Dispos 19:1071-1079.
16. Hildebrandt MA, Salavaggione OE, Martin YN, et al. 2004. Human SULT1A3 pharmacogenetics: gene duplication and functional genomic studies. Biochem Biophys Res Commun 321:870-878.
17. Hines RN, McCarver DG. 2002. The ontogeny of human drug-metabolizing enzymes: phase I oxidative enzymes. J Pharmacol Exp Ther 300:355-360.
18. Hinson JA, Reid AB, McCullough SS, et al. 2004. Acetaminophen-induced hepatotoxicity: role of metabolic activation, reactive oxygen/nitrogen species, and mitochondrial permeability transition. Drug Metab Rev 36:805-822.
19. Johnsrud EK, Koukouritaki SB, Divakaran K, et al. 2003. Human hepatic CYP2E1 expression during development. J Pharmacol Exp Ther 307:402-407.
20. Leeder JS. 2003. Developmental and pediatric pharmacogenomics. Pharmacogenomics 4:331-341.
21. Leeder JS, Gaedigk R, Marcucci KA, et al. 2005. Variability of CYP3A7 in human fetal liver. J Pharmacol Exp Ther 314:626-635.
22. Litovitz TL, Klein-Schwartz W, Rodgers GCJ, et al. 2002. 2001 Annual report of the American Association of Poison Control Centers Toxic Exposure Surveillance System. Am J Emerg Med 20:391-452.
23. Lu AYH, Levin W. 1972. Partial purification of cytochromes P-450 and P-448 from rat liver microsomes. Biochem Biophys Res Commun 46:1334-1339.
24. McCarver DG, Hines RN. 2002. The ontogeny of human drug metabolizing enzymes: phase II conjugation enzymes and regulatory mechanisms. J Pharmacol Exp Ther 300:361-366.
25. Miki Y, Nakata T, Suzuki T, et al. 2002. Systemic distribution of steroid sulfatase and estrogen sulfotransferase in human adult and fetal tissues. J Clin Endocrinol Metab 86:2734-2742.
26. Mitchell AA. 2003. Systematic identification of drugs that cause birth defects - A new opportunity. New Engl J Med 349:2556-2559.
27. Reiter C, Weinshilboum RM. 1982a. Acetaminophen and phenol: substrates for both a thermostable and a thermolabile form or human platelet phenol sulfotransferase. J Pharmacol Exp Ther 221:43-51.
28. Reiter C, Weinshilboum RM. 1982b. Platelet phenol sulfotransferase activity: correlation with sulfate conjugation of acetaminophen. Clin Pharmacol Ther 32:612-621.
29. Richard K, Hume R, Kaptein E, et al. 2001. Sulfation of thyroid hormone and dopamine during human development: Ontogeny of phenol sulfotransferases and arylsulfatase in liver, lung and brain. J Clin Endocrinol Metab 86:2734-2742.
30. Rollins DE, von Bahr C, Glaumann H, et al. 1979. Acetaminophen: Potential toxic metabolite formed by human fetal and adult liver microsomes and isolated fetal liver cells. Science 205:1414-1416.
31. Stanley EL, Hume R, Coughterie MW. 2005. Expression profiling of human fetal cytosolic sulfotransferases involved in steroid and thyroid hormone metabolism and in detoxification. Mol Cell Endocrinol 240:32-42.
32. Strassburg CP, Strassburg A, Kneip S, et al. 2002. Developmental aspects of human hepatic drug glucuronidation in young children and adults. Gut 50:259-265.
33. Team RDC. 2006. R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing.
34. Torfs CP, Katz EA, Bateson TF, et al. 1996. Maternal medications and environmental exposures as risk factors for gastroschisis. Teratology 54:84-92.
35. Vietri M, Pietrabissa A, Mosca F, et al. 2001. Human adult and foetal liver suphotransferases: inhibition by mefenamic acid and salicylic acid. Xenobiotica 31:153-161.
36. Weinshilboum RM, Adjei AA. 2005. Sulfate conjugation: Pharmacogenetics and pharmacogenomics. In: Pacifici GM, Coughtrie MWH, editors. Human Cytosolic Sulfotransferases. Boca Raton, FL: CRC Press, Taylor and Francis Group. p 61-78.
37. Weinshilboum RM, Otterness DM, Aksoy IA, et al. 1997. Sulfotransferase molecular biology: cDNAs and genes. FASEB J 11:3-14.
38. Werler M, Mitchell AA, Shapiro S. 1992. First trimester maternal medication use in relation to gastroschisis. Teratology 45:361-367.
39. Werler MM, Mitchell AA, Hernandez-Diaz S, et al. 2005. Use of over-the-counter medications during pregnancy. Am J Obstet Gynecol 193: 771-777.
40. Werler MM, Sheehan JE, Mitchell AA. 2002. Maternal medication use and risks of gastroschisis and small intestinal atresia. Am J Epidemiol 155:26-31.